Abstract:Objective To study the clinical effect of combined kidney transplantation and splenic fossa auxiliary heterotopic liver transplantation to treat highly sensitized recipients. Methods Combined kidney transplantation and splenic fossa auxiliary heterotopic liver transplantation from the same donor was used to treat a highly sensitized recipient with panel reactive antibodies (PRA) >50% and pre-existing donor specific antibodies (DSA). The hyperacute rejection and the function of renal after the transplant were observed. Serum samples were also collected before and after reperfusion of the liver and each time points after the transplant surgery to detect the antibody level using Luminex technology. Results The kidney function was excellent, without hyperacute rejection, after the transplant surgery and the creatinine was 141 umol/L on 6th day. But on 7th day after transplant, the creatinine was increased and the acute rejection of transplant kidney was happened. By plasmapheresis, ATG and IVIG, the acute rejection was controlled. And on 60th day after transplant, the creatinine was 131 umol/L. After reperfusion of the liver and at 3 house postoperatively, the fluorescent value of pre-existing antibodies down to below 500. On 7th day after transplant, the fluorescent value increased and slowly decreased at later time points. Antigen test using Luminex technology shows that pre-existing DSA were DR8 and DQ6. After reperfusion of the liver and at 3 house postoperatively, the fluorescent value of DR8 and DQ6 all down to below 500. DR8 rose to 17,311 on 7th day after transplant and 28th day 7,471, 60th day 12,258. DQ6 rose to 6,054 on 7th day after transplant and 28th day 625, 60th day 1,004. Conclusions Combined kidney transplantation and splenic fossa auxiliary heterotopic liver transplantation from the same donor appears to be solving ability for the problem of kidney transplantation in highly sensitized patients. Although it can protect the renal graft from risk of hyperacute rejection, the acute rejection should be prevented actively. Discussion Transplanting a renal graft in the presence of DSA or highly level PRA likely results in hyperacute rejection and graft loss. The level of antibodies after reperfusion of the liver and at 3 hour postoperatively showed the strong ability of transplanted liver absorbs the preformed antibodies. Thus, it protected the renal graft from hyperacute rejection. In the subsequent observations, the increase of pre-existing DSA and antibodies levels showed that acute rejection has happened. Through clinical intervention, the acute rejection was relieved and each observations decreased on 28th day after transplant. The levels of DSA and antibodies increased on 60th day after transplant, but the function of renal transplantation was normal. The likely reason was that liver transplantation may be played a role during the induction of peripheral tolerance. What is needed in this case is long-term clinical observation and it is not enough explained the long-term clinical effect of combined kidney transplantation and splenic fossa auxiliary heterotopic liver transplantation. But, the success in preventing the renal graft from hyperacute rejection, undoubtedly, opened the door for transplantation strategy in highly sensitized recipients.

Clinical characteristics of 15 cases of renal transplantation with pre - exsiting donor - specific antibody

Renal transplantation across the donor-specific antibody barrier: Graft outcome and cancer risk after desensitization therapy

Impact of Alloantibody Strength in Crossmatch Negative DSA Positive Kidney Transplantation

A modified perioperative regimen for deceased donor kidney transplantation in presensitized recipients without prior desensitization therapy

Double Filtration Plasmapheresis Combined with Daclizumab in the Treatment for Sensitized Recipients of Cadaver Kidney Transplantation

Influence of de novo donor-specific antibody on early renal allograft function recovery.

Pre-transplant donor specific antibodies in ABO incompatible kidney transplantation – data from the Swiss transplant cohort study

Understanding the Significance of Low-Level Preformed Donor-Specific Anti-Hla Antibodies in Renal Transplant Patients.

Preoperative Treatment and Prognosis Observation in Sensitized Recipients of Kidney Transplantation

Clinical effects of double filtration plasmapheresis for sensitized recipients of cadaver kidney transplantation

AB96. the First Clinical Research in the World of Combined Kidney Transplantation and Splenic Fossa Auxiliary Heterotopic Liver Transplantation in Highly Sensitized Recipients

The detrimental effect of donor-specific antibodies is irrespective of its level in highly-immunized living donor kidney transplant recipients: A case-control series

Clinical Characteristics and Strategies of Early Stage Antibody-Mediated Rejection after Renal Transplantation

Management experience and effect analysis of highly sensitized recipients before living kidney transplantation

ABO‐incompatible Living Kidney Transplantation

Abo-Incompatible Living Kidney Transplantation

Current Diagnosis and Therapy States of Donor Specific Antibodies in Kidney Transplantation

High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome

Clinical observation on the removal of donor specific antibody by double filtration plasmapheresis in renal transplant recipients

A personalised delisting strategy enables successful kidney transplantation in highly sensitised patients with preformed donor‐specific anti HLA antibodies

Pre-transplant crossmatch-negative donor-specific anti-HLA antibody predicts acute antibody-mediated rejection but not long-term outcomes in kidney transplantation: an analysis of the Korean Organ Transplantation Registry